Genscript Biotech Corporation

Equities

1548

KYG3825B1059

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 09:08:34 17/07/2024 BST			5-day change	1st Jan Change
13.22 ^HKD	+6.27%		+47.38%	-33.43%

07-10	Genscript Biotech to Use 68,054 RSA Shares for Scheme, Over 425 Million Shares Available Under General Mandate	MT
07-09	Genscript Biotech Grants Restricted Shares Under Incentive Scheme	MT

An unknown buyer acquired an unknown stake in Genscript Biotech Corporation from KPCB China.

January 14, 2018

An unknown buyer acquired an unknown stake in Genscript Biotech Corporation (SEHK:1548) from KPCB China on January 15, 2018. An unknown buyer completed the acquisition of an unknown stake in Genscript Biotech Corporation (SEHK:1548) from KPCB China on January 15, 2018.

Latest news about Genscript Biotech Corporation

Genscript Biotech to Use 68,054 RSA Shares for Scheme, Over 425 Million Shares Available Under General Mandate	07-10	MT
Genscript Biotech Grants Restricted Shares Under Incentive Scheme	07-09	MT
Genscript Biotech Corporation Announces Board and Committee Changes	07-05	CI
Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results	07-04	MT
Genscript Biotech Units Receive Milestone Payment of $30 Million	06-28	MT
Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees	06-23	CI
GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market	06-18	CI
Genscript Biotech CEOs to Receive Shares Under Restricted Share Scheme	06-13	MT
Hong Kong Stocks Rebound Following More than Expected Growth in China’s Manufacturing Sector	06-03	MT
GenScript Biotech Draws Attention from US Congress Members; Shares Tank 18%	06-03	MT
GenScript Biotech Shares Drop After U.S. Lawmakers Scrutinize Chinese Ties	06-03	DJ
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	06-01	RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	05-31	RE
Legend Expects to Log Profit in 2026	05-15	MT
Legend Biotech's Loss Narrows in Q1 as Revenue Surges	05-14	MT
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications	05-13	CI
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing	04-23	CI
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	04-23	MT
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	04-17	MT
Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee	04-12	CI
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	04-09	MT
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication	03-19	MT
Genscript Biotech Issues 444,598 Shares to Three Grantees Under Restricted Share Scheme	03-14	MT
Genscript Biotech's 2023 Loss Widens; Misses Revenue Estimates	03-11	MT
Transcript : Genscript Biotech Corporation, 2023 Earnings Call, Mar 11, 2024	03-10

Chart Genscript Biotech Corporation

Duration

Period

More charts

Company Profile

Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Genscript Biotech Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.593 USD

Average target price

3.091 USD

Spread / Average Target

+93.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENSCRIPT BIOTECH CORPORATION	-33.43%	3.39B
MODERNA, INC.	+21.87%	47.96B
IQVIA HOLDINGS INC.	+0.78%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.26%	31.6B
ICON PUBLIC LIMITED COMPANY	+20.87%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.11%	14.56B
MEDPACE HOLDINGS, INC.	+45.42%	14.14B
BIO-TECHNE CORPORATION	+2.64%	12.58B

Other Biotechnology & Medical Research